Excipients are an important part of a formulation, but regulatory hurdles and economics make it difficult to bring new excipients
to market. Despite these obstacles, excipient producers see opportunity for innovation and in working more closely with formulators
to improve the understanding of excipients in a formulation as well in meeting specific needs when formulating poorly water-soluble
drugs and in nanotechnology.
Quality by design offers opportunity
On a developmental basis, excipient makers point to important trends affecting innovation in excipients. "Definition and testing
of excipient functionality is an issue as well as the education of formulators in the use of excipients," says Alen Guy, vice-president
of research and development at JRS Pharma (Patterson, NY). "Education is an area that is sadly lacking. It has certainly led to repeats of academic work that has been
forgotten owing to poor research and reading by formulators. I would also point to quality by design as both a challenge and
an opportunity for innovation. If the pharmaceutical companies more fully understand the excipients they use, then perhaps
they will work more closely with the excipient manufacturers to develop even better excipients," he says.
Advancing poorly water-soluble drugs
Other producers see opportunity in poorly water-soluble drugs. "New excipients should focus on the very often poor solubility
and poor resorption into the body of many new chemical entities coming from active pharmaceutical ingredient (API) research,"
says Dr. Ralf Widmaier, marketing manager at BASF SE (Ludwigshafen, Germany). "The need for highly efficient, yet versatile solubilizers, and especially polymeric solubilizers
is one of the most important topics within the next years."
Brian Koblinski, market development manager of pharmaceutical excipients at Dow Wolff Cellulosics, a business unit of the Dow Chemical Company (Midland, MI) points to several areas for innovation. "For development, there is a focus on excipients that are fully characterized
in structure/property relationships and understanding how these properties affect drug-release performance across the spectrum
of low- to high-solubility actives and developing dosage forms with in vitro–in vivo correlations, salvaging poorly soluble and poorly absorbed new chemical entities, and enabling oral delivery of large molecules."
Nanotechnology and excipients
As the field of nanotechnology widens, so does the role of excipients. In a recent analysis, BCC Research outlined some key developments in excipients in nanotechnology (1).
One application involves nanocoatings that are used to protect small tablets and assist in the ingestion of high therapeutic
doses (600–800 mg). BCC Research offers as an example BASF's ibuprofen DC 85 formulation with a nanolayer that protects against
temperature influences and speeds up production (700,000 tablets/h as compared with 200,000 normally) (1, 2). Nanocoatings
reduce the amount of lubricants needed and eliminate the need for wet granulation and compacting (1).
In another example, Justin Hanes and a team of Johns Hopkins University scientists discovered that coating nanoparticles with a low-molecular-weight polyethylene glycol excipient allows them to
penetrate vagina membranes and serve as sustained-release carriers for therapeutic agents for treating cervical cancer. Also,
incorporating nanoparticles into quick-dissolving edible thin strips can improve film properties, reports the BCC study (1).
Nanotechnology is also being applied to human serum albumin (hSA), an approach taken by Abraxis BioScience (Los Angeles, CA) with its "Nab" (nanoparticle albumin-bound) technology platform that combines hSA with an API for delivering
protein drugs. "With the European Medicines Agency's 2006 reversal of its decision on transgenic drugs, transgenic albumin could be a future excipient option," reports the
BCC study. GTC Biotherapeutic's (Framingham, MA) "ATryn" (recombinant human antithrombin), an anticlotting protein secreted into the milk of transgenic goats,
was initially rejected for marketing approval by the European Medicines Agency in February 2006. EMEA later reversed is decision
and approved the drug upon further review in August 2006.